GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Napazimone

Company
Pharming Technologies B.V.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for Napazimone and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05650229

    Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

    Not yet reported Pharming Technologies B.V. 180 participants Est. completion 2027-11 55 sites Stand-alone
    Other conditions: Primary Mitochondrial Disease
    View official trial listing →
  • Recruiting NCT NCT07514338

    Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease

    Not yet reported Pharming Technologies B.V. 140 participants Est. completion 2029-03-31 23 sites Stand-alone
    Other conditions: Mitochondrial Diseases
    View official trial listing →
  • Completed NCT NCT03056209

    Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers

    Not yet reported Yungjin Pharm. Co., Ltd. 60 participants Est. completion 2018-04-16 1 site Stand-alone
    Other conditions: MELAS Syndrome, Mitochondrial Respiratory Chain Deficiencies
    View official trial listing →
  • Completed NCT NCT03888716

    A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease

    Not yet reported Abliva AB 72 participants Est. completion 2021-03-16 2 sites Stand-alone
    Other conditions: Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies, MELAS Syndrome, Mitochondrial Myopathies
    View official trial listing →
  • Completed NCT NCT04643249

    Drug-drug Interaction Study of KL1333 in Healthy Subjects

    Not yet reported Abliva AB 14 participants Est. completion 2020-12-17 1 site Stand-alone
    Other conditions: Mitochondrial Disease
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Napazimone, KL1333

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.